Lendormin

Brotizolam, the active ingredient in Lendormin, is a benzodiazepine presented as a tablet for oral use. It acts on the central nervous system to enhance GABA‑mediated inhibition and is prescribed for the short‑term treatment of insomnia and other sleep disorders in adult patients requiring rapid onset of sleep.

GNH USA supplies Lendormin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved bulk and finished‑product shipments to meet global demand across diverse healthcare settings.

Brotizolam, a benzodiazepine sedative‑hypnotic, is employed for short‑term management of sleep disturbances.

- Insomnia: facilitates rapid sleep onset and helps maintain sleep throughout the night in adult patients during brief treatment courses. - Transient sleep disturbance: reduces nighttime awakenings and improves overall sleep quality for individuals experiencing temporary sleep disruption. - Sleep disorders: provides symptomatic relief for acute sleep‑related conditions such as jet‑lag or shift‑work associated insomnia. - Sleep onset latency issues: shortens the time required to fall asleep in patients with delayed sleep onset.

Brotizolam may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Drowsiness: feeling of excessive sleepiness during daytime. - Dizziness: light‑headed sensation or loss of balance. - Headache: mild to moderate cranial pain. - Fatigue: reduced energy and increased tiredness. - Amnesia: short‑term memory impairment. - Muscle relaxation: decreased muscle tone.

Serious or Rare Side Effects: - Respiratory depression: slowed or shallow breathing, especially with other depressants. - Dependence or addiction: risk of psychological or physical reliance with prolonged use. - Withdrawal seizures: convulsions occurring after abrupt discontinuation. - Severe allergic reactions: rash, itching, swelling, or anaphylaxis. - Paradoxical agitation: increased anxiety, aggression, or restlessness. - Depression or suicidal thoughts: emergence of mood changes.

When prescribing Brotizolam, clinicians should observe several safety considerations to minimize risk.

- Avoid alcohol: concurrent consumption can intensify sedation and respiratory depression. - Use caution in elderly: increased sensitivity may lead to falls and profound drowsiness. - Monitor renal or hepatic impairment: reduced clearance may require dose adjustment. - Do not operate machinery: impaired psychomotor performance can affect driving or equipment use. - Store at room temperature: keep in the original container, protect from moisture and light.

Brotizolam interacts with several drug classes; awareness of these interactions helps prevent adverse outcomes.

Major Interactions (Avoid): - Alcohol: additive central nervous system depression may cause severe sedation. - Opioids: combined use increases risk of profound respiratory depression and overdose. - Other benzodiazepines: cumulative sedative effects can lead to excessive CNS depression. - Barbiturates: synergistic depression of respiratory and cardiac function.

Moderate Interactions (Monitor Closely): - Antidepressants (SSRIs, SNRIs): may enhance sedative properties and cause increased drowsiness. - Antihistamines: additive sleepiness and impaired alertness. - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): can raise Brotizolam plasma concentrations, requiring dose review.